Basket Updated
0
Items added
The TGF-β Antibody #3711 detects recombinant TGF-β1, TGF-β2, and TGF-β3. The antibody also detects endogenous levels of the TGF-β1 precursor proteins. The different sizes we have listed represent the precursor TGF-β protein (45kDa), the mature dimer form (25kDa) and the monomer (12kDa).We do not usually detect the mature TGF-β at 25 kDa because mature TGF-β is composed of two polypeptides that are disulfide-linked. Therefore under reducing conditions, these polypeptides are separated and observed as a single band at 12 kDa. However, we have shown that the TGF-β Antibody #3711 can detect the mature form of TGF-β by using recombinant protein.TGF-β is rapidly exported from the cell and therefore may be difficult to detect in tissue or cell lysates. In human platelet samples, we observe two strong bands, with the larger band likely being the precursor (uncleaved) form at 45kDa and the smaller being the monomer at 12kDa.
An antibody shouldn’t be one of the variables in your experiment. Find out why customers rank CST highest for antibody specificity and sensitivity.
U.S. Patent No. 6,441,140, directed to the production of a novel class of motif-specific, context-independent antibodies, highly useful for the identification of subclasses of protein kinase substrates.
CST and Amoy Diagnostics announced the expansion of their collaboration to use CST antibodies in companion diagnostics to aid growing oncology needs in China.
Get information on ordering or contacting Cell Signaling Technology. CST is happy to answer your questions. Select the team you need to contact.
Feb 2008, CST continued collaboration with AstraZeneca to provide CST’s PhosphoScan® Platform for kinase inhibitor proteomic profiling.
Cell Signaling Technology, a leading provider of antibodies, kits and services, announced today that it has won two Life Science Industry Awards® for "Best Antibodies" and "Most Useful Website."
Cell Signaling Technology and Leica Biosystems Partner to Enable Companion Diagnostic (CDx) Development
Announce partnership with this local 1% for the Planet startup to help share and promote best practices for sustainability. Also, to encourage other companies to do the same by promoting recent sponsorship of NSTC as part of our ESR activities.
CST and The Michael J. Fox Foundation (MJFF) announce a partnership to develop high-quality monoclonal antibodies against promising Parkinson’s disease (PD) targets.
MEDx and CST announce expansion of their ongoing partnership for companion diagnostic (CDx) development using CST® antibodies to meet growing demand in China.
Co-staining with multiple antibodies is a low-content form of multiplex analysis that be achieved using different host species or fluorophore conjugates.
A scientific resource for the 14-3-3 protein domain containing information on structure, function, and binding to phospho-serine and phospho-threonine motifs.
Will an antibody validated for WB perform as expected in an IF experiment? Here, we compare an IF-validated mAb from CST to one from another vendor.
Beyond our recommended immunofluorescence protocols, here are additional considerations when planning your IF imaging experiment.
A Hallmark of Cancer, sustaining proliferative signaling is used by cancer cells to stimulate growth and relies on Akt, MAPK/Erk, and MTOR pathways.
Lymphoid lineage cells can be characterized using antibodies for cell type-specific markers, allowing cells to be visualized using flow cytometry or IHC.